AiCure

Shire

AbbVie outlines rationale for Shire offer

Wednesday, June 25, 2014 02:14 PM

Following Shire’s confirmed rejection of Abbvie’s offer on June 20, AbbVie has outlined its strategic rationale for, and background to, its proposal to the board of Shire of $34.74 in cash and 0.7988 ordinary shares of New AbbVie for each Shire share. The proposal represented an indicative value of $78.63 on May 29 (the latest practicable date before the proposal was made). While this cash and share mix is valued at $77.57 per share as of June 24, any firm offer made by AbbVie under Rule 2.7 of the Code will need to be equivalent to $78.63 per share.

More... »


Shire confirms rejection of AbbVie proposal

Friday, June 20, 2014 01:47 PM

Shire has confirmed it has rejected the May 30 unsolicited and highly conditional proposal from AbbVie regarding a possible cash and share offer for Shire. 

More... »


arGEN-X, Shire Pharmaceuticals partner for therapeutic antibodies

Friday, June 6, 2014 01:03 PM

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has entered into a long-term strategic alliance with Shire Pharmaceuticals.

More... »

Shire acquires Lumena Pharmaceuticals

Monday, May 12, 2014 12:21 PM

Shire will acquire Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for an upfront payment of $260 million in cash, plus a payment at closing and near-term contingent milestone payments related to ongoing clinical trials.

More... »

Rolf Stahel joins board of Ergomed as non-executive chairman

Thursday, May 8, 2014 02:08 PM

Ergomed, a U.K.-based drug development and services company, has appointed Rolf Stahel to its board as non-executive chairman.

More... »

Shire acquires Fibrotech for $75M

Friday, May 2, 2014 11:32 AM

Shire, a global specialty biopharmaceutical company, has acquired Fibrotech, an Australian biopharmaceutical company developing a new class of drugs associated with fibrosis, for an up-front payment of $75 million plus certain development and regulatory milestone payments.

More... »

PharmaTimes recognizes top U.S. clinical researchers

Tuesday, November 19, 2013 01:00 PM

Winners of the U.S. Clinical Researcher of the Year competition were announced following an intense finals day hosted by partner SAS at its global headquarters in Cary, N.C.

More... »

U.S. Clinical Researchers of the Year announced

Tuesday, November 12, 2013 08:00 AM

The 2013 U.S. Clinical Researchers of the Year winners have been revealed at the Umstead Hotel in North Carolina, U.S.

More... »

Shire to acquire ViroPharma for $4.2 billion

Monday, November 11, 2013 02:55 PM

Shire and ViroPharma have entered a merger agreement in which Shire will acquire all the outstanding shares of ViroPharma in a cash deal valued at a total of $4.2 billion.

More... »

Shire updates reorganization program, Basingstoke site consolidated

Friday, November 8, 2013 12:10 PM

Shire Pharmaceuticals has updated its “One Shire” program and has initiated an employee consultation process at its site in Basingstoke.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs